Benitec Biopharma Inc. (BNTC) intrinsic value & 10-year financials
Benitec Biopharma Inc. (BNTC) has a Graham intrinsic value of $122.04 per share. At $8.11 on Oct 17, 2026, the stock trades 93% below that value.
- Graham intrinsic value
- $122.04
- Share price (Oct 17, 2026)
- $8.11
- Price vs Graham value
- 93% below
- Market cap
- $293.7M
- Revenue (FY2025)
- —
- Revenue growth (8-yr CAGR)
- -71.6%
- ROIC (10-yr avg)
- 562.4%
- Free cash flow (FY2025)
- -$23.6M
BNTC 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$37.9M | -$1.05 | -$23.6M | — | 2123.0% |
| FY2024 | $0 | -$21.8M | -$0.61 | -$19.6M | — | 775.6% |
| FY2023 | $75.0K | -$19.6M | -$0.52 | -$18.0M | -25441.3% | 1497.9% |
| FY2022 | $73.0K | -$18.2M | -$0.08 | -$15.9M | -24457.5% | 2932.0% |
| FY2021 | $59.0K | -$13.9M | -$0.06 | -$13.1M | -23044.1% | -2135.7% |
| FY2020 | $97.0K | -$8.3M | — | -$7.6M | -8537.1% | -1272.9% |
| FY2019 | $11.6M | $2.6M | — | $4.4M | 22.4% | 17.1% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Benitec Biopharma Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Benitec Biopharma Inc. returns on capital have been average, hovering around 8.0% ROIC over the decade.
Benitec Biopharma Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Benitec Biopharma Inc. is modeled at -71.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $122.04 per share.